Team


Miguel Barreto

CEO and Co-Founder

Ph.D. in Information Systems


Miguel is a seasoned data scientist with 15 years of experience in academic and industry projects. This background give him a perfect vision of the data science landscape and he apply this vision directly to business. His leadership has been rewarded with the “Venture leaders prize (2015)” and to be elected for the Magazine L’Hebdo as one of the 100 people that will build the Switzerland of tomorrow (2015).

Shawna McCallin

COO and Co-Founder

Phage & Microbiome Scientist


Shawna is a phage scientist with 10 years experience, including involvment in phase l/ll phage clinical trials for E. coli diarrhea and S. aureus carriage. She is the author of numerous academic publications and is active in adressing clinical and regulatory aspects of phage therapy. She is a member of the editorial board of the new scientific journal PHAGE: Therapy, Applications, and Research, and a member of the executive board of the International Society of Viruses of Microbes.

Diogo Leite

Co-Founder

M.Sc. in Information and Knowledge Systems


Diogo has a master in Information and Knowledge Systems. His Master thesis topic was machine learning applied to predicting the interaction between two organisms based only on their genomic information. He is the author of several publications on computational prediction of bacteria relationships through omics data analysis and machine learning.

Xavier Brochet

Co-Founder

Ph.D. in Information Systems


Xavier has a Ph.D in Bioinformatics from the University of Montpelier, France. He is a senior bioinformatician with over 12 years of experience. He has worked in the most renowned bioinformatics institutes in Europe including Swiss Institute of Bioinformatics, European Bioinformatic Institute (England), National Center for Scientific Research (France) among others.

Scientific advisory
board


Grégory Resch, PhD

Department of Fundamental Microbiology, University of Lausanne

Project Director and Group Leader Phage and phage-lysin therapy.


Dr. Gregory Resch has been working in the field of new antimicrobial development since more than 15 years, with a peculiar interest in original pathogen-specific strategies. Two of these approaches include bacteriophage therapy (or phage therapy), and phage-lysin therapy.

YokAi Que, PDPhD

Department of Intesive Care Medicine, Bern University Hospital (Inselspital), Bern

Senior Physician


The core of the research of Dr Que’s group is to conceive, elaborate and/or test novel strategies to combat complex infections, with the ultimate goal of uncovering novel strategies to fight the increasing threat of antibiotic resistance

Prof. Carlos Peña, PhD

Institute for Information and Communication Technologies, University of Applied Sciences and Arts of Western Switzerland, HEIGVD

Group leader Computational Intelligence for Computational Biology


Its research focuses on the development of computational intelligence methodologies and their application to real world problems, specially those related with life sciences and biomedical engineering involving data analysis and predictive modeling.